UTIBRON

Drug Sunovion Pharmaceuticals Inc.
Total Payments
$4.7M
Transactions
59,811
Doctors
16,232
Companies
2

Payment Trends by Year

Year Amount Transactions Doctors
2020 $1,257 15 0
2019 $3,029 15 0
2018 $544,752 5,582 2,833
2017 $4.1M 54,199 15,134

Payments by Nature

Nature of Payment Amount Transactions Share
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2.8M 1,223 60.6%
Food and Beverage $796,956 47,899 17.0%
Travel and Lodging $651,655 3,363 13.9%
Unspecified $358,102 123 7.6%
Consulting Fee $24,673 7 0.5%
Education $19,638 7,196 0.4%

Payments by Type

General
$4.3M
59,688 transactions
Research
$358,102
123 transactions

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
A MULTI CENTER RANDOMIZED DOUBLE BLIND DOUBLE DUMMY 2 PERIOD CROSS OVER AND ACTIVE CONTROLLED STUDY TO ASSESS THE EFFICACY SAFETY AND TOLERABILITY OF INDACATEROL AND OR GLYCOPYRRONIUM BROMIDE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE Novartis Pharmaceuticals Corporation $346,822 0
A 12 WEEK TREATMENT MULTI CENTER RANDOMIZED DOUBLE BLIND PARALLEL GROUP PLACEBO AND ACTIVE CONTROLLED STUDY TO ASSESS THE EFFICACY SAFETY AND TOLERABILITY OF QVA149 INDACATEROL MALEATE AND OR GLYCOPYRRONIUM BROMIDE IN COPD PATIENTS WITH MODERATE TO SEVERE AIRFLOW LIMITATION Novartis Pharmaceuticals Corporation $6,993 0
A MULTI CENTER RANDOMIZED DOUBLE BLIND DOUBLE DUMMY 2 PERIOD CROSS OVER AND ACTIVE CONTROLLED STUDY TO ASSESS THE EFFICACY SAFETY AND TOLERABILITY OF INDACATEROL AND OR GLYCOPYRRONIUM BROMIDE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC OBSTRUCTIVE PULMONA Novartis Pharmaceuticals Corporation $4,286 0

Top Doctors Receiving Payments for UTIBRON — Page 3

Doctor Specialty Location Total Records
, M.D.F.C.C.P Pulmonary Disease Miami, FL $17,078 38
, M.D Pulmonary Disease Houston, TX $16,915 37
, MD Pulmonary Disease Milwaukee, WI $16,580 38
, MD Internal Medicine Monterey Park, CA $16,218 47
, MD Critical Care Medicine Walterboro, SC $16,064 42
, MD Specialist Harvey, IL $16,000 32
, M.D Allergy & Immunology Lincoln, NE $15,839 41
, MD Pulmonary Disease Rockport, ME $15,778 39
, MD Internal Medicine Middle Village, NY $15,749 44
Michael Ehrie — Ashland, KY $15,330 44
, MD Internal Medicine Whitehall, PA $15,215 34
, MD Internal Medicine Newport Beach, CA $14,486 39
, D.O Internal Medicine Livonia, MI $14,436 41
, MD Pulmonary Disease Ashtabula, OH $14,361 38
, M.D Allergy Medford, OR $14,317 38
Christos Kapogiannis — North Dartmouth, MA $14,289 32
, M.D Pulmonary Disease Charlotte, NC $14,259 53
, MD PA Pulmonary Disease Sugar Land, TX $14,167 33
, M.D Pulmonary Disease Los Angeles, CA $14,082 35
, M.D Pulmonary Disease Houston, TX $13,796 39
, MD Critical Care Medicine Decatur, GA $13,657 45
, MD Pulmonary Disease Salem, VA $13,444 39
, MD Critical Care Medicine Cincinnati, OH $13,105 55
, MD Pulmonary Disease Snellville, GA $12,493 35
, MD Pulmonary Disease Milwaukee, WI $12,467 40
«12345…650»

Manufacturing Companies

Product Information

  • Type Drug
  • Total Payments $4.7M
  • Total Doctors 16,232
  • Transactions 59,811

About UTIBRON

UTIBRON is a drug associated with $4.7M in payments to 16,232 healthcare providers, recorded across 59,811 transactions in the CMS Open Payments database. The primary manufacturer is Sunovion Pharmaceuticals Inc..

Payment data is available from 2017 to 2020. In 2020, $1,257 was paid across 15 transactions to 0 doctors.

The most common payment nature for UTIBRON is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($2.8M, 60.6% of total).

UTIBRON is associated with 3 research studies, including "A MULTI CENTER RANDOMIZED DOUBLE BLIND DOUBLE DUMMY 2 PERIOD CROSS OVER AND ACTIVE CONTROLLED STUDY TO ASSESS THE EFFICACY SAFETY AND TOLERABILITY OF INDACATEROL AND OR GLYCOPYRRONIUM BROMIDE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE" ($346,822).